Aegerion Pharma (AEGR) Posts Q4 Loss of 66c/Share; Guides FY12 Cash Burn

Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) reported Q4 EPS of ($0.66), $0.14 worse than the analyst estimate of ($0.52).

Aegerion is also providing full-year 2012 estimated cash burn guidance of between $43 and $48 million.

For earnings history and earnings-related data on Aegerion Pharmaceuticals, Inc. (AEGR) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c